Solid-phase synthesis of thymosin beta 4: chemical and biological characterization of the synthetic peptide.
Low. T L TL; Wang. S S SS; Goldstein. A L AL
Key Findings
- Synthetic thymosin beta‑4 can be produced by solid‑phase synthesis and is chemically identical to the natural peptide.
- The synthetic peptide matches natural thymosin beta‑4 in activity assays (terminal deoxynucleotidyltransferase induction and macrophage migration inhibition).
- The study confirms the proposed structure of thymosin beta‑4 through multiple analytical techniques.
Practical Outcomes
- For biohackers, this means commercially available synthetic thymosin beta‑4 should be equivalent to natural sources, giving confidence in its purity and activity. However, the paper provides no guidance on dosing, safety, or real‑world performance, so further human studies are needed before practical protocols can be developed.
Summary
Scientists figured out how to make thymosin beta‑4 in the lab using a solid‑phase method, and the lab‑made version looks and works just like the natural peptide in basic lab tests. This shows that synthetic thymosin beta‑4 is chemically pure and biologically active, but the study doesn’t give any dosing or human‑effect information.
Abstract
The chemical synthesis of thymosin beta 4 using a solid-phase procedure has been accomplished. The synthetic product was found to be homogeneous on paper electrophoresis at pH 6.5, high-performance liquid chromatography on a reversed-phase column, and isoelectric focusing using polyacrylamide gels. The synthetic material was also shown to be identical with the natural thymosin beta 4 by tryptic peptide mapping, amino acid compositional analyses, and polyacrylamide gel isoelectric focusing. Biologically, synthetic thymosin beta 4 was found to be as active as the natural compound in a terminal deoxynucleotidyltransferase induction assay and in a macrophage migration inhibition assay. The proposed structure of the peptide hormone was thus confirmed by a chemical synthesis.
Study Information
pubmed
1983
1983-02-15T00:00:00.000Z
10.1021/bi00273a004